Compositions comprising platelet derived extracellular vesicles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient therapies for immune and inflammatory disorders that minimize the amount of medication required for desired immunosuppressive and anti-inflammatory effects while minimizing undesired side effects, particularly for patients who do not respond well to existing treatments.
Innovation Solution
A composition comprising platelet-derived extracellular vesicles, administered in combination with immunosuppressive and/or anti-inflammatory drugs, is used to treat immune and inflammatory disorders such as graft-versus-host disease, autoimmune disorders, and neuroinflammation-associated neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher doses of immunosuppressive and anti-inflammatory drugs are administered to achieve desired therapeutic effects, then the efficacy in treating immune and inflammatory disorders is improved, but the undesired side effects increase
Solution Approach 1:
The patent uses platelet-derived extracellular vesicles as an intermediary substance that mediates the therapeutic effect between the administration and the immune system. These vesicles carry immunosuppressive and anti-inflammatory cargo that can modulate immune responses without requiring high doses of traditional drugs, thereby achieving therapeutic efficacy while minimizing side effects.
Solution Approach 2:
The patent changes the parameter of drug dosage by combining platelet-derived extracellular vesicles with lower doses of immunosuppressive and anti-inflammatory drugs. This parameter change allows achieving the desired therapeutic effect with reduced drug concentrations, thereby reducing the harmful side effects associated with higher doses.
2Object-affected harmful factors
If lower doses of immunosuppressive and anti-inflammatory drugs are administered to reduce side effects, then the undesired side effects are minimized, but the therapeutic efficacy decreases
Solution Approach 1:
The patent merges platelet-derived extracellular vesicles with immunosuppressive and anti-inflammatory drugs to create a combined therapeutic composition. This merging allows the vesicles to enhance the efficacy of lower drug doses, ensuring that therapeutic effectiveness is maintained even when drug concentrations are reduced to minimize side effects.
3Ease of operation
If established medication regimes are used for treating immune and inflammatory disorders, then the treatment approach is standardized and easy to implement, but the response is inadequate for patients who do not respond well to existing treatments
Solution Approach 1:
The patent employs a composite therapeutic composition consisting of platelet-derived extracellular vesicles combined with immunosuppressive and anti-inflammatory drugs. This composite approach provides a novel treatment modality that can be effective for patients who do not respond adequately to established medication regimes, while still maintaining a standardized and implementable treatment protocol.
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3A~3D
AI summary
The invention relates to a composition comprising platelet derived extracellular vesicles, e.g., human platelet lysate derived extracellular vesicles, for use in the prevention and/or treatment of an immune disorder and/or of an inflammatory disorder in a subject, wherein the composition is administered to the subject.